At the 20th Congress of the European Hematology Association (EHA), Christian Gisselbrecht, MD, of Paris Diderot University, Paris, France, highlights the unmet clinical needs and emerging therapeutic options for patients with diffuse large B-cell lymphoma (DLBCL). Research is moving towards targeted agents that utilize the improved understanding of disease biology in patient subgroups with the poorest prognoses.